Natalizumab-induced pneumonitis

J Neurol. 2022 Mar;269(3):1688-1690. doi: 10.1007/s00415-021-10811-3. Epub 2021 Sep 22.

Authors

Stefania Kaninia^{1

2}, Anthony J Edey³, Nick A Maskell^{2

4}, Claire M Rice^{5

6}

Affiliations

¹ Department of Neurology, North Bristol NHS Trust, Bristol, UK.
² Bristol Medical School, University of Bristol, Bristol, UK.
³ Department of Radiology, North Bristol NHS Trust, Bristol, UK.
⁴ Department of Respiratory Medicine, North Bristol NHS Trust, Bristol, UK.
⁵ Department of Neurology, North Bristol NHS Trust, Bristol, UK. c.m.rice@bristol.ac.uk.
⁶ Bristol Medical School, University of Bristol, Bristol, UK. c.m.rice@bristol.ac.uk.

No abstract available

Publication types

Letter

MeSH terms

Humans
Immunologic Factors / adverse effects
Multiple Sclerosis* / drug therapy
Multiple Sclerosis, Relapsing-Remitting*
Natalizumab / adverse effects
Pneumonia* / chemically induced
Pneumonia* / drug therapy

Substances

Immunologic Factors
Natalizumab